{"article_title": "Biotech Sector Addicted to M&A Drug -- Heard on the Street", "article_keywords": ["sector", "biotech", "used", "ma", "unlike", "valuations", "visit", "drug", "heard", "street", "week", "yellen", "addicted", "shot", "went", "stocks"], "article_url": "http://www.wsj.com/articles/biotech-sector-addicted-to-m-a-drug-heard-on-the-street-1425063974", "article_text": "Unlike on a visit to Capitol Hill last year, Janet Yellen didn\u2019t criticize biotech valuations when she went before Congress this week. But that doesn\u2019t mean investors should let their guard down.\n\nSince the Federal Reserve chairwoman last July used biotech stocks as an example of possible froth, the sector has mostly shot higher. In fact, over the past two years, the Nasdaq Biotechnology Index has outperformed the NYSE Arca...", "article_metadata": {"article.template": "snippet", "article.created": "2015-02-27T19:06:00.000Z", "article.section": "Markets", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Pharmaceuticals deal-making is a boon for biotech stocks. Amid the euphoria, valuations call for caution.", "title": "Biotech Sector Addicted to M&A Drug", "image": {"src": "https://si.wsj.net/public/resources/images/BN-HE036_0227bi_G_20150227134402.jpg", "alt": "Pharmaceuticals deal-making is a boon for biotech stocks. Amid the euphoria, valuations call for caution", "identifier": "https://si.wsj.net/public/resources/images/BN-HE036_0227bi_D_20150227134402.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB12729948149543524457504580488121852077184&headline=Pharmaceuticals%20deal-making%20is%20a%20boon%20for%20biotech%20stocks.%20Amid%20the%20euphoria%2C%20valuations%20call%20for%20caution&weburl=http://www.wsj.com/articles/SB12729948149543524457504580488121852077184"}}, "page.site.product": "WSJ", "keywords": "Bristol-Myers Squibb,BMY,Salix Pharmaceuticals,SLXP,Valeant Pharmaceuticals International,VRX.T,VRX,biotechnology,political,general news,sciences,technologies,equity markets,commodity,financial market news,pharmaceuticals,health care,life sciences", "news_keywords": "Bristol-Myers Squibb,BMY,Salix Pharmaceuticals,SLXP,Valeant Pharmaceuticals International,VRX.T,VRX,biotechnology,political,general news", "article.headline": "Pharmaceuticals deal-making is a boon for biotech stocks. Amid the euphoria, valuations call for caution", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-HE036_0227bi_E_20150227134402.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-HE036_0227bi_D_20150227134402.jpg"}}, "description": "Pharmaceuticals deal-making is a boon for biotech stocks. Amid the euphoria, valuations call for caution.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB12729948149543524457504580488121852077184&headline=Pharmaceuticals%20deal-making%20is%20a%20boon%20for%20biotech%20stocks.%20Amid%20the%20euphoria%2C%20valuations%20call%20for%20caution&weburl=http://www.wsj.com/articles/SB12729948149543524457504580488121852077184", "user.type": "nonsubscriber", "article.page": "Heard on the Street", "page.content.format": "responsive", "article.summary": "Pharmaceuticals deal-making is a boon for biotech stocks. Amid the euphoria, valuations call for caution.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-02-27T19:06:00.000Z", "dj.asn": "i-f261", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "image_count": 2, "word_count": 415}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Pharmaceuticals deal-making is a boon for biotech stocks. Amid the euphoria, valuations call for caution.", "title": "Biotech Sector Addicted to M&A Drug", "url": "http://www.wsj.com/articles/biotech-sector-addicted-to-m-a-drug-heard-on-the-street-1425063974", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-HE036_0227bi_G_20150227134402.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Charley Grant", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Biotech Sector Addicted to M&A Drug", "article.type": "Heard on the Street", "article.id": "SB12729948149543524457504580488121852077184", "user.exp": "default", "article.updated": "2015-02-27T19:06:00.000Z"}, "_id": "\"57477af46914bd0286fe1605\"", "article_summary": "Since the Federal Reserve chairwoman last July used biotech stocks as an example of possible froth, the sector has mostly shot higher.\nUnlike on a visit to Capitol Hill last year, Janet Yellen didn\u2019t criticize biotech valuations when she went before Congress this week.\nIn fact, over the past two years, the Nasdaq Biotechnology Index has outperformed the NYSE Arca...\nBut that doesn\u2019t mean investors should let their guard down."}